tirzepatide triple agonist vs. Retatrutide: The Science Behind Dual and Triple-Agonist Metabolic Peptides Tirzepatide, a New Era of

Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Zepbound during pregnancy

The progression in weight loss results follows that receptor count almost perfectly: Each additional receptor target adds roughly 5 to 8 percentage points of weight loss

Thanks to Jaimie for her help and guidance

Compared to the first-generation GLP-1R agonist, tirzepatide has three critical improvements: first, many residues in peptide backbone are changed to obtain GIPR-activating activity

What endpoints are typically measured in preclinical research with these compounds?# Common endpoints in preclinical research with tirzepatide and retatrutide include body weight trajectories, body composition via DEXA or MRI in animal models, fasting and postprandial glucose, HbA1c or equivalent glycemic markers, plasma insulin and glucagon dynamics, hepatic triglyceride content, and indirect calorimetry measures such as resting energy expenditure and respiratory exchange ratio